Table 4 Comparison of clinical and laboratory data between patients with HFS and those without HFS
Factor | HFS (n = 58) | Non-HFS (n = 109) | P value | |
|---|---|---|---|---|
Sex | Male | 21(36.2%) | 51(46.8%) | 0.189 |
Female | 37(63.8%) | 58(53.2%) | ||
Age | 59 ± 9.76 | 61 ± 14.60 | 0.352 | |
BMI(kg/m2) | 23.93 ± 2.17 | 23.34 ± 2.32 | 0.114 | |
Dose intensity (mg·m2) | 30 | 12(20.7%) | 50(45.9%) | 0.001* |
40 | 46(79.3%) | 59(54.1%) | ||
Group B symptoms | Yes | 25(43.1%) | 39(35.8%) | 0.354 |
No | 33(56.9%) | 70(64.2%) | ||
Clinical stage | I-II | 32(55.2%) | 45(41.3%) | 0.086 |
III-IV | 26(44.8%) | 64(58.7%) | ||
Presence of large tumour masses | Yes | 7(12.1%) | 21(19.3%) | 0.236 |
No | 51(87.9%) | 88(80.7%) | ||
Pathological type | HL | 11(19.0%) | 13(11.9%) | 0.248 |
NHL | 47(81.0%) | 96(88.1%) | ||
History of gallstones | Yes | 8(13.8%) | 3(2.8%) | 0.006* |
No | 50(86.2%) | 106(97.2%) | ||
Hepatitis | Yes | 12(20.7%) | 11(10.1%) | 0.058 |
No | 46(79.3%) | 98(89.9%) | ||
Treatment cycle | 5.47 ± 2.00 | 5.36 ± 1.52 | 0.721 | |
Curative effect | CR + PR | 47(81.0%) | 97(89.0%) | 0.155 |
SD + PD | 11(19.0%) | 12(11.0%) | ||
Baseline ALT | 30.28 ± 15.93 | 14.14 ± 4.91 | < 0.001* | |
Baseline AST | 29.17 ± 8.79 | 19.27 ± 4.29 | < 0.001* | |
Baseline GGT | 46.24 ± 35.60 | 19.23 ± 7.38 | < 0.001* | |
Baseline TBIL | 13.62 ± 5.04 | 13.51 ± 4.37 | 0.889 | |
Baseline MONO | 0.41 ± 0.12 | 0.42 ± 0.46 | 0.860 | |